Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : US bins 60m contaminated Johnson and Johnson covid jabs

06/11/2021 | 11:50am EDT

Regulators in the US have ruled that 60 million doses of the Johnson & Johnson coronavirus vaccine will need to be discarded because of suspected contamination, according to reports.  

The doses were produced in a factory in Baltimore operated by Emergent BioSolutions, where federal regulators have been conducting a review over the course of several weeks.

The Food and Drug Administration (FDA) has yet to decide if Emergent can reopen the premises, which have been closed for around two months as a result of the regulatory concerns.

The FDA plans to allow the distribution of 10 million doses across the United States or to other countries, but would issue a warning they cannot guarantee that Emergent followed good manufacturing practices. 

The fate of over 170 million doses of vaccine have been left uncertain after they were put on hold when a contamination was discovered. 

Emergent workers accidentally contaminated a batch of Johnson & Johnson’s vaccine with a key ingredient used to produce AstraZeneca’s leaving the FDA unsure of what to do with 100 million Johnson & Johnson vaccines, and 70 million AstraZeneca doses.  

Emergent production was paused and its responsibility to produce the AstraZeneca vaccine stripped. The FDA ordered Johnson & Johnson to assert direct control over the manufacturing of its vaccine there.

The Biden administration had planned on sharing doses of both Johnson & Johnson and AstraZeneca vaccines as part of its strategy to distribute vaccines to other countries, but it was forced to delay this while the FDA completed a review of the Baltimore facility.

The post US bins 60m contaminated Johnson and Johnson covid jabs appeared first on CityAM.

© City AM, source Newspaper

All news about JOHNSON & JOHNSON
06/17JOHNSON & JOHNSONá : Eying border reopening, Mexico begins J&J vaccine rollout i..
AQ
06/17Canada Vaccine Panel Recommends Against AstraZeneca PLC for Second Dose
DJ
06/17US to Spend $3.2 Billion on COVID Treatments Research
MT
06/16ASTRAZENECAá : Second Phase of Covid-19 Vaccinations Begins
AQ
06/16EU Says Johnson & Johnson May Not Meet Vaccine Supply Commitment After Jabs C..
MT
06/15US, EU Vow to Provide COVID-19 Vaccine to Two-Thirds of World's Population by..
MT
06/15JOHNSON & JOHNSONá : Aspen to Dispatch 300 000 J&J Vaccines for Teachers
AQ
06/15JOHNSON & JOHNSONá : Donated US vaccines arrive for Mexican border cities
AQ
06/15THE LATEST : Johnson & Johnson shots arrive in Mexico from US
AQ
06/15FEDEXá : Makes its First COVID-19 Vaccine Delivery to Mexico, of 1.35 Million Jo..
MT
More news
Financials (USD)
Sales 2021 92 812 M - -
Net income 2021 22 227 M - -
Net Debt 2021 314 M - -
P/E ratio 2021 19,9x
Yield 2021 2,53%
Capitalization 435 B 435 B -
EV / Sales 2021 4,69x
EV / Sales 2022 4,39x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 183,67 $
Last Close Price 165,22 $
Spread / Highest target 23,5%
Spread / Average Target 11,2%
Spread / Lowest Target -4,37%
EPS Revisions
Managers and Directors
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON4.98%435 090
ROCHE HOLDING AG12.75%328 768
PFIZER, INC.7.25%220 997
NOVARTIS AG2.73%210 424
ABBVIE INC.7.23%202 939
ELI LILLY AND COMPANY31.61%201 995